Economic returns to investment in AIDS treatment in low and middle income countries

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Resch, Stephen ^a   Korenromp, Eline ^b,c   Stover, John ^d   Blakley, Matthew ^b   Krubiner, Carleigh ^e   Thorien, Kira ^e   Hecht, Robert ^e   Atun, Rifat ^b,f  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b TUBERCULOSIS AND MALARIA   (Switzerland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d AVENIR HEALTH   (United States)

^e RESULTS FOR DEVELOPMENT INSTITUTE   (United States)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DEVELOPING COUNTRY; FUNDING; HEALTH CARE AVAILABILITY; HEALTH CARE FINANCING; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; INVESTMENT; LOWEST INCOME GROUP; MALARIA; OPPORTUNISTIC INFECTION; PRODUCTIVITY; PUBLIC-PRIVATE PARTNERSHIP; RESOURCE ALLOCATION; SENSITIVITY ANALYSIS; SURVIVAL RATE; TERMINAL CARE; TUBERCULOSIS; ADULT; CHILD; ECONOMICS; EMPLOYMENT; HUMAN; INCOME; STATISTICS; TIME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CHILD; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; EMPLOYMENT; HUMANS; INCOME; INVESTMENTS; TIME FACTORS;

EID: 80053577320     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025310     Document Type: Article

References (70)

1. UNAIDS (2010) Global Report: UNAIDS report on the global AIDS epidemic. Available: http://www.unaids.org/globalreport/Global_report.htm Accessed: 2011 September 13.
2. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents - recommendations for a public health approach. Available: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf Accessed: 2011 August 4.
3. World Health Organization HIV/AIDS Programme, UNAIDS, UNICEF (2010) Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector Geneva World Health Organization.
4. UNAIDS (2009) AIDS epidemic update: November 2009 Geneva UNAIDS.
5. Bishai D, Colchero A, Durack DT, (2007) The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS 21: 1333-1340.
6. Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA, (2005) Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ 331: 1431-1437.
7. Stover J, Korenromp EL, Blakley M, Komatsu R, Viisainen K, et al. (2011) Long-term costs and health impact of continued global fund support for antiretroviral therapy. PLoS One 6: e21048.
8. Sabot O, Cohen J, Hsiang M, Kahn J, Basu S, et al. (2010) Costs and financial feasibility of malaria elimination. Lancet 376: 1604-1615.
9. Murray C, Evans DB, Acharya A, Baltussen R, (2000) Development of WHO guidelines on generalized cost-effectiveness analysis. Health Economics 9: 235-251.
10. Fox MP, Rosen S, MacLeod WB, Wasunna M, Bii M, et al. (2004) The impact of HIV/AIDS on labour productivity in Kenya. Trop Med Int Health 9: 318-324.
11. Larson BA, Fox MP, Rosen S, Bii M, Sigei C, et al. (2009) Do the socioeconomic impacts of antiretroviral therapy vary by gender? A longitudinal study of Kenyan agricultural worker employment outcomes. BMC Public Health 9: 240.
12. Larson BA, Fox MP, Rosen S, Bii M, Sigei C, et al. (2008) Early effects of antiretroviral therapy on work performance: preliminary results from a cohort study of Kenyan agricultural workers. AIDS 22: 421-425.
13. The Global Fund to Fight AIDS Tuberculosis and Malaria (2010) Financial and health impacts of continued support to the three diseases: long-term estimates Geneva The Global Fund to Fight AIDS Tuberculosis and Malaria.
14. Stover J, Johnson P, Zaba B, Zwahlen M, Dabis F, et al. (2008) The Spectrum projection package: improvements in estimating mortality, ART needs, PMTCT impact and uncertainty bounds. Sex Transm Infect 84 (Suppl 1): i24-i30.
15. Mahy M, Lewden C, Brinkhof MW, Dabis F, Tassie JM, et al. (2010) Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy. Sexually transmitted infections 86 (Suppl 2): ii28-34.
16. The Global Fund to Fight AIDS Tuberculosis and Malaria (2010) Price and Quality Reporting system.
17. World Health Organization (2009) Global Price Reporting Mechanism. Available: http://www.who.int/hiv/amds/gprm/en/ Accessed: 2010 May 26.
18. The Global Fund to Fight AIDS Tuberculosis and Malaria (2010) The Global Fund Results report 2010: innovation and impact Geneva.
19. Adam T, Evans DB, Murray CJ, (2003) Econometric estimation of country-specific hospital costs: WHO-CHOICE. Cost Eff Resour Alloc 1: 3.
20. Renaud-Thery F, Avila-Figueroa C, Stover J, Thierry S, Vitoria M, et al. (2011) Utilization patterns and projected demand of antiretroviral drugs in low- and middle-income countries. AIDS research and treatment 2011: 749041.
21. Joint United Nations Programme on HIV/AIDS (2009) AIDS epidemic update: November 2009 Geneva UNAIDS.
22. Haacker M, (2004) HIV/AIDS: The Impact on the Social Fabric and the Economy. In: Haacker M, editors. The Macroeconomics of HIV/AIDS Geneva International Monetary Fund.
23. Booysen FlR, Arntz T, (2003) The methodology of HIV/AIDS impact studies: a review of current practices. Social Science & Medicine 56: 2391-2405.
24. Wandel S, Egger M, Rangsin R, (2008) Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect 84 (Suppl 1): i31-i36.
25. Marston M, Todd J, Glynn JR, Nelson KE, Rangsin R, et al. (2007) Estimating 'net' HIV-related mortality and the importance of background mortality rates. AIDS 21 (Suppl 6): S65-71.
26. Todd J, Glynn JR, Marston M, Lutalo T, Biraro S, et al. (2007) Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy. AIDS 21 (Suppl 6): S55-63.
27. Yamano T, Jayne T, (2004) Measuring the Impacts of Working-Age Adult Mortality on Small-Scale Farm Households in Kenya. World Development 32: 91-119.
28. World Health Organization HIV/AIDS Programme (2009) Rapid advice: Antiretroviral therapy for HIV infection in adults and adolescents Geneva.
29. King JT Jr, Justice AC, Roberts MS, Chang CC, Fusco JS, (2003) Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med Decis Making 23: 9-20.
30. Fox MP, McCoy K, Larson BA, Rosen S, Bii M, et al. (2010) Improvements in physical wellbeing over the first two years on antiretroviral therapy in western Kenya. AIDS Care 22: 137-145.
31. Beard J, Feeley F, Rosen S, (2009) Economic and quality of life outcomes of antiretroviral therapy for HIV/AIDS in developing countries: a systematic literature review. AIDS Care 21: 1343-1356.
32. Morineau G, Vun MC, Barennes H, Wolf RC, Song N, et al. (2009) Survival and quality of life among HIV-positive people on antiretroviral therapy in Cambodia. AIDS Patient Care STDS 23: 669-677.
33. Bussmann H, Wester CW, Ndwapi N, Grundmann N, Gaolathe T, et al. (2008) Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 22: 2303-2311.
34. Thirumurthy H, Saravanan R, Srinivas G, Jafri A, Sreevidya J, et al. (2008) The impact of antiretroviral therapy on socioeconoic outcomes of HIV-infected patients in Tamil Nadu family care continuum program, India. XVII International AIDS Conference. Mexico City, Mexico.
35. Habyarimana J, Mbakile B, Pop-Eleches C, (2007) HIV/AIDS, ARV Treatment and Worker Absenteeism: Evidence from a Large African Firm.
36. Goldstein MPG-Z, J, Thirumurthy H, (2009) The household impacts of treating HIV/AIDS in Developing Countries. In: Yifu Lin J, Pleskovic B, editors. Annual World Bank Conference on Development Economics Global: People, Politics, and Globalization Washington DC World Bank.
37. Thirumurthy H, J G-Z, M G, (2008) The economic impact of AIDS treatment: labor supply in Western Kenya. Journal of Human Resources 43: 511-552.
38. Linnemayr S, Lawson BS, Glick P, Wagner G, (2011) Economic Status and Coping Mechanisms of Individuals Seeking HIV Care in Uganda. Journal of African Economies 20: 505-529.
39. Thirumurthy H, Jafri A, Srinivas G, Arumugam V, Saravanan RM, et al. (2011) Two-year impacts on employment and income among adults receiving antiretroviral therapy in Tamil Nadu, India: a cohort study. AIDS 25: 239-246.
40. Sgombich X, Bahamondes L, Cid C, (2006) Quality of life in work, absenteeism, and HAART in workers living with HIV. XVI International AIDS Conference. Toronto, Canada.
41. Eholie S, Nolan M, (2003) Antiretroviral treatment can be cost-savings for industry and life-saving for workers: a case study from Cote d'Ivoire's private sector. In: Moatti J, Barnett T, Coriat B, Souteyrand Y, Dumoulin J, editors. Economics of AIDS and access to HIV/AIDS care in developing countries: issues and challenges Paris, France Agence Nationale de Recherches sur le Sida pp. 329-346.
42. E B, van Zyl A, Myer-Rath G, Letlape O, Ndibongo B, et al. (2009) A cost-benefit analysis of employer provided highly active antiretroviral therapy to HIV positive employees of a large South African mining company International Health Economics Association Beijing.
43. Rosen S, Ketlhapile M, Sanne I, Desilva MB, (2008) Differences in normal activities, job performance and symptom prevalence between patients not yet on antiretroviral therapy and patients initiating therapy in South Africa. AIDS 22 (Suppl 1): S131-139.
44. Coetzee C, (2008) The impact of highly active antiretroviral treatment (HAART) on employment in Khayelitsha. South African Journal of Economics 76: S76-S85.
45. Muirhead D, Kumaranayake L, Hongoro C, Charalambous S, Grant A, et al. (2006) Health care costs, savings, and productivity benefits resulting from a large employer sponsored ART program in South Africa. XVI International AIDS Conference. Toronto, Caanada.
46. International Labour Organization (2009) LABORSTA Labour Statistics Database 2 Feb 2010 ed.
47. World Bank (2009) World Development Indicators Online 8 Oct 2009 ed World Bank.
48. Barnighausen T, Hosegood V, Timaeus IM, Newell ML, (2007) The socioeconomic determinants of HIV incidence: evidence from a longitudinal, population-based study in rural South Africa. AIDS 21 (Suppl 7): S29-38.
49. Gillespie S, Kadiyala S, Greener R, (2007) Is poverty or wealth driving HIV transmission? AIDS 21 (Suppl 7): S5-S16.
50. Tsai AC, Chopra M, Pronyk PM, Martinson NA, (2009) Socioeconomic disparities in access to HIV/AIDS treatment programs in resource-limited settings. AIDS Care 21: 59-63.
51. Haacker M, (2010) HIV/AIDS, Economic Growth, Inequality. In: Sahn D, editors. The Socioeconomic Dimensions of HIV/AIDS in Africa Ithaca Cornell University Press.
52. Mahal A, Canning D, Odumosu K, Okonkwo P, (2008) Assessing the economic impact of HIV/AIDS on Nigerian households: a propensity score matching approach. AIDS 22 (Suppl 1): S95-101.
53. Beegle K, DeWeerdt J, Dercon S, (2007) Orphanhood, and the long-run impact on children Center for the studies of African economics.
54. UNAIDS, UNICEF, USAID (2004) Children on the Brink: A Joint Report of New Orphan Estimates and Framework for Action.
55. Stover J, Bollinger L, Walker N, Monasch R, (2007) Resource needs to support orphans and vulnerable children in sub-Saharan Africa. Health Policy Plan 22: 21-27.
56. Foster G, Williamson J, (2000) A review of current literature on the impact of HIV/AIDS on children in sub-Saharan Africa. AIDS 14 (Suppl 3): S275-284.
57. Bollinger L, Stover J, (2007) Finanacial resources required to achieve universal access to HIV prevention, treatment, care and support: methodology for care and treatment- methodological annex III.
58. Tan-Torres Edejer T, (2003) Making choices in health: WHO guide to cost-effectiveness analysis Geneva World Health Organization.
59. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. (1996) Cost-effectiveness in Health and Medicine New York Oxford University Press.
60. Lu C, Schneider MT, Gubbins P, Leach-Kemon K, Jamison D, et al. (2010) Public financing of health in developing countries: a cross-national systematic analysis. Lancet 375: 1375-1387.
61. Izazola-Licea JA, Wiegelmann J, Aran C, Guthrie T, de Lay P, et al. (2009) Financing the response to HIV in low-income and middle-income countries. J Acquir Immune Defic Syndr 52: S119-S126.
62. Cuddington JT, Hancock JD, (1995) The macroeconomic impact of AIDS in Malawi: a dualistic, labour surplus economy. J Afr Econ 4: 1-28.
63. Thurlow J, Gow J, George G, (2009) HIV/AIDS, growth and poverty in KwaZulu-Natal and South Africa: an integrated survey, demographic and economy-wide analysis. J Int AIDS Soc 12: 18.
64. Ventelou B, Moatti JP, Videau Y, Kazatchkine M, (2008) 'Time is costly': modelling the macroeconomic impact of scaling-up antiretroviral treatment in sub-Saharan Africa. AIDS 22: 107-113.
65. Jeffries K, Siphanmbe H, Kinghorn A, (2006) The economic impact of HIV/AIDS in Botswana Econsult Pty Ltd.
66. Bell C, Devarajan S, Gersbach H, (2004) Thinking about the long-run economic costs of AIDS. In: Haacker M, editors. The Macroeconomics of HIV/AIDS Geneva International Monetary Fund.
67. Becker GS, Philipson TJ, Soares RR, (2003) The quantity and quality of life and the evolution of world inequality. Cambridge: National Bureau of Economic Research. Working Paper 9765 Working Paper 9765.
68. World Health Organization (2010) WHO-CHOICE Cost-effectiveness thresholds. Available: http://www.who.int/choice/costs/CER_thresholds/en/index.html Accessed 2011 August 7.
69. Jamison DT, Sachs JD, Wang J, (2001) The Effect of the AIDS Epidemic on Economic Welfare in Sub-Saharan Africa Commission on Macroeconomics and Health.
70. Viscusi K, Aldy J, (2003) The value of a statistical life: A critical review of market estimates from around the world. Journal of Risk and Uncertainty 27: 5-76.